EUVIMED · CrossrefZeitschrift
Blood Cancer Journal
ISSN 2044-5385 · Springer Science and Business Media LLC
Neueste Artikel
Real-world treatment patterns and clinical outcomes in relapsed/refractory multiple myeloma across Asia: a multicenter Asian Myeloma Network study (AMN010)
Clinical characteristics, treatment, and long-term outcomes in 987 patients with splenic marginal zone lymphoma to inform treatment and surveillance strategies
Correction: Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study
CAPA induction followed by sequential radiotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma: a multicentre, single-arm, phase 2 trial
Denosumab in multiple myeloma patients with severe renal impairment: a multicenter phase 2 study
STAG2 mutation predicts superior posttransplant survival in acute myeloid leukemia treated with low-intensity induction
Biomarkers of cellular senescence and their association with frailty, clinical outcomes, and survival in multiple myeloma
Nivolumab consolidation in patients with double and triple hit high-grade B-cell lymphoma in complete metabolic remission after DA-EPOCH-R
Socioeconomic deprivation does not affect survival outcomes in patients with mantle cell lymphoma: evidence from a German nationwide study
Beyond binary: graded frailty assessment and outcomes after CAR-T cell therapy in relapsed/refractory multiple myeloma
Safety and efficacy of port use for CAR T-cell infusion in large B-cell lymphoma
Impact of socioeconomic status on treatment and survival in multiple myeloma in Australia
Infectious complications following bispecific antibody or CAR T therapy in adult patients with hematologic malignancies: a retrospective database analysis
Impact of granulocyte colony-stimulating factors on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma
Bosmolisib (BR101801), a novel PI3K-δ/γ and DNA-PK inhibitor for relapsed/refractory patients with peripheral T-cell lymphoma: a phase I study
Venetoclax, azacitidine, and G-CSF targeting molecular residual disease in CBFB::MYH11 AML resistant to high-dose cytarabine
Single agent selinexor is active in patients with myelofibrosis refractory or intolerant to JAK inhibitors
Preclinical and clinical efficacy of the HDAC6 inhibitor ricolinostat in combination with BCR pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia
Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study
Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients
The search for safe and effective CAR-T targets in AML
Monoclonal gammopathy of clinical significance: a multisystem review
Clinical outcomes of CD3xCD20 bispecific antibodies in patients with central nervous system involvement by lymphoma
Immune effector cell-associated enterocolitis post-BCMA directed CAR T-cell therapy: insights from a multicenter case series
Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma
Current treatment algorithm: diffuse large B cell lymphoma
Immune escape mechanisms and therapeutic advances in virus-associated hematological malignancies
Immunoglobulin supplementation and longer dosing intervals reduce risk of infections in patients with RRMM treated with teclistamab
NFκB/IL-6/JAK2/STAT axis in myelofibrosis is a key vulnerability that is targetable and relevant to JAK2 inhibitor treatment resistance
EUVIMED